Tissue Regenix Group plc (TSSNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tissue Regenix Group plc (TSSNF) trades at $0.005 with AI Score 43/100 (Grade C). Tissue Regenix Group plc is a medical technology company focused on tissue engineering and regenerative medicine. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TSSNF: TSSNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TSSNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TSSNF: 2/3 scored disciplines lean bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Tissue Regenix Group plc (TSSNF) Healthcare & Pipeline Overview
Tissue Regenix Group plc develops and commercializes regenerative medicine technologies, including its dCELL decellularization process, targeting the biosurgery, orthopedics, dental, and cardiac markets. The company operates internationally, offering solutions for tissue repair and regeneration, but faces challenges common to the biotechnology sector, including profitability and regulatory hurdles.
What Is the Investment Thesis for TSSNF?
Tissue Regenix Group plc presents a compelling, albeit speculative, investment thesis centered on its proprietary dCELL technology and its applications in the growing regenerative medicine market. The company's negative P/E ratio of -7.06 and negative profit margin of -6.8% indicate current challenges in achieving profitability. However, the 41.8% gross margin suggests potential for improved financial performance as the company scales its operations and commercializes its product pipeline. Key growth catalysts include expanding market adoption of its DermaPure and OrthoPure XT products, as well as potential regulatory approvals for new applications of its dCELL technology. A key risk factor is the company's reliance on successful commercialization and market penetration to offset its current losses.
Based on FMP financials and quantitative analysis
TSSNF Key Highlights
Gross Margin of 41.8% indicates potential for profitability with increased sales volume.
- Operates in the regenerative medicine market, a sector projected to experience significant growth.
- dCELL technology provides a unique competitive advantage in tissue decellularization.
- Negative P/E ratio of -7.06 reflects current losses but also potential for future earnings growth.
- Beta of 1.43 suggests higher volatility compared to the overall market.
Who Are TSSNF's Competitors?
TSSNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.8M | 44 |
| HITC Healthcare Integrated Technologies, Inc. | $0.29 | +0.00% | $52.8M | 38 |
| HRPMF Herantis Pharma Oyj | $3.51 | +0.00% | $59.5M | 44 |
| KDEVF Karolinska Development AB (publ) | $0.26 | +0.00% | $68.9M | 56 |
| MCIOF MCI Onehealth Technologies Inc. | $0.55 | -1.10% | $54.0M | 46 |
| VRTX Vertex Pharmaceuticals Incorporated | $552.06 | +4.52% | $140B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $242.61 | +6.12% | $32.5B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TSSNF's Key Strengths?
Proprietary dCELL technology
- Diverse product portfolio
- Presence in multiple therapeutic areas
- Established distribution network
What Are TSSNF's Weaknesses?
Negative profitability
- Reliance on successful commercialization
- Limited financial resources
- OTC market listing
What Could Drive TSSNF Stock Higher?
Potential regulatory approvals for new applications of dCELL technology.
- Expansion of DermaPure sales in the wound care market.
- Increased adoption of OrthoPure XT in orthopedic procedures.
What Are the Key Risks for TSSNF?
Negative return on equity (-2.4%) — the business is not currently generating profit on shareholder capital.
- Competition from larger medical device companies.
- Regulatory hurdles and delays in product approvals.
- Patent expiration and intellectual property challenges.
- Negative profitability and reliance on future funding.
- OTC market listing and associated risks.
What Are the Growth Opportunities for TSSNF?
- Expansion of DermaPure Market: Tissue Regenix has the opportunity to expand the market for DermaPure, its decellularized dermal allograft, for burn treatment and reconstructive surgery. The global market for wound care is projected to reach $22 billion by 2028, offering a significant opportunity for Tissue Regenix to increase its market share through targeted marketing and clinical studies demonstrating the efficacy of DermaPure.
- OrthoPure XT Adoption in Orthopedics: OrthoPure XT, a scaffold for orthopedic tissue regeneration, can drive growth by capturing a larger share of the orthopedic market. The global orthopedic market is expected to reach $60 billion by 2027, with a growing demand for regenerative solutions. Tissue Regenix can capitalize on this trend by partnering with orthopedic surgeons and hospitals to promote the benefits of OrthoPure XT in cartilage repair and joint reconstruction.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with leading medical device companies and establishing distribution agreements in key international markets can accelerate revenue growth. This would allow Tissue Regenix to leverage the established sales and marketing networks of its partners to reach a wider customer base and increase product adoption. Focus on partnerships in Europe and Asia, where regenerative medicine is gaining traction, can be particularly beneficial.
- New Product Development and Innovation: Investing in research and development to expand its product pipeline and develop new applications for its dCELL technology can drive long-term growth. Focusing on areas such as cardiovascular tissue repair and regenerative dentistry can open up new market opportunities and diversify the company's revenue streams. Continuous innovation is crucial for maintaining a competitive edge in the rapidly evolving biotechnology industry.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its products in key markets, such as the United States and Europe, is essential for expanding market access and driving sales growth. This includes pursuing FDA clearance for new indications of its existing products and conducting clinical trials to support regulatory submissions. Successful regulatory approvals can significantly enhance the company's credibility and market position.
What Are TSSNF's Competitive Advantages?
- Proprietary dCELL technology creates a barrier to entry.
- Established relationships with surgeons and hospitals.
- Growing portfolio of regenerative medicine products.
- Intellectual property protection through patents.
What Does TSSNF Do?
Tissue Regenix Group plc, founded in 2006 and based in Garforth, United Kingdom, is a medical technology company specializing in tissue engineering and regenerative medicine. The company's core technology, dCELL, is a soft tissue decellularization process that removes DNA and cellular material from animal and human soft tissue, allowing for the creation of biocompatible scaffolds for tissue repair and regeneration. Tissue Regenix operates through several divisions: BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac, each focused on specific applications of its technology. Key products include DermaPure, a decellularized dermal allograft for skin repair; SurgiPure XD, a porcine dermal matrix for hernia repair; and OrthoPure XT, a scaffold for orthopedic tissue regeneration. The company also offers a range of bone grafting materials, including ConCelltrate 100 and MatrixCellect 100. Tissue Regenix's products are sold in the United States and internationally, targeting a broad range of surgical and regenerative medicine applications. The company aims to provide innovative solutions for tissue damage and disease, leveraging its proprietary technologies to improve patient outcomes.
What Products and Services Does TSSNF Offer?
- Develops and commercializes tissue engineering and regenerative medicine products.
- Utilizes dCELL technology to decellularize animal and human tissues for biocompatible scaffolds.
- Offers DermaPure for skin repair and replacement.
- Provides SurgiPure XD for hernia and body wall defect repair.
- Markets OrthoPure XT for orthopedic tissue regeneration.
- Offers bone grafting materials like ConCelltrate 100 and MatrixCellect 100.
- Develops products for biosurgery, orthopedics, dental, and cardiac applications.
How Does TSSNF Make Money?
- Develops proprietary tissue engineering technologies.
- Manufactures and sells decellularized tissue products.
- Targets hospitals, surgeons, and medical professionals.
- Generates revenue through direct sales and distribution agreements.
What Industry Does TSSNF Operate In?
Tissue Regenix operates within the biotechnology industry, specifically in the regenerative medicine and tissue engineering segment. This market is characterized by rapid innovation, increasing demand for advanced medical solutions, and stringent regulatory requirements. The competitive landscape includes companies like BSTG, HITC, HRPMF, KDEVF, and MCIOF, which are developing and marketing competing tissue regeneration and repair products. Tissue Regenix aims to capture a share of this growing market through its proprietary dCELL technology and expanding product portfolio.
Who Are TSSNF's Key Customers?
- Hospitals and surgical centers
- Orthopedic surgeons
- Plastic surgeons
- Dental professionals
Company Profile
Tissue Regenix Group plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Garforth, GB. The company is led by CEO Daniel R. Lee. TSSNF has traded publicly since 2016.
TSSNF Valuation & Market Position
Relative to its peer group, TSSNF's quantitative score of 43/100 is roughly in line with the peer average of 46/100.
Key Financial Metrics
Return on equity for Tissue Regenix Group plc stands at -2.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -81.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.2%, the inverse of the P/E and a quick read on earnings relative to price.
TSSNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could drive growth.
- The company has made strides in securing new partnerships, enhancing its market position and expanding its reach in regenerative medicine.
- Recent media coverage has focused on the increasing demand for regenerative therapies, which aligns well with Tissue Regenix's offerings.
Bear Case
- Concerns have emerged regarding the company's cash flow management, raising questions about its ability to sustain operations without additional funding.
- Some community members express skepticism about the scalability of its technology, suggesting that widespread adoption may face hurdles.
- Recent regulatory challenges in the healthcare sector have created an uncertain environment, impacting investor confidence in biotech firms like Tissue Regenix.
- Market perception remains cautious, as competitors are making significant advancements, potentially overshadowing Tissue Regenix's innovations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TSSNF Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 9, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 10, 2019
TSSNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TSSNF.
Price Targets
Wall Street price target analysis for TSSNF.
TSSNF MoonshotScore
What does this score mean?
The MoonshotScore rates TSSNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Daniel R. Lee
CEO
Daniel R. Lee serves as the CEO of Tissue Regenix Group plc. His background includes extensive experience in the medical device and biotechnology industries. Prior to joining Tissue Regenix, he held leadership positions at various healthcare companies, focusing on commercial strategy, product development, and market access. He brings a wealth of knowledge in driving growth and innovation in the regenerative medicine sector.
Track Record: Since becoming CEO, Daniel R. Lee has focused on expanding the company's product portfolio and strengthening its commercial operations. Key achievements include securing strategic partnerships, driving revenue growth in key markets, and advancing the development of new regenerative medicine products. His leadership has been instrumental in navigating the challenges of the biotechnology industry and positioning Tissue Regenix for future success.
TSSNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tissue Regenix Group plc may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, be undergoing restructuring, or face regulatory issues. This tier contrasts with exchanges like NYSE or NASDAQ, which have stringent listing requirements, including minimum share price, market capitalization, and financial reporting standards. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for limited liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure
- Lower liquidity and wider bid-ask spreads
- Potential for price manipulation
- Higher risk of delisting or bankruptcy
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Presence of a reputable management team
- Proprietary technology and intellectual property
- Partnerships with established medical institutions
- Positive clinical trial results (if available)
- Growing revenue and market share
TSSNF Healthcare Stock FAQ
What does the AI Score mean for TSSNF?
TSSNF holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Tissue Regenix Group plc is a medical technology company focused on tissue engineering and regenerative medicine. Their dCELL technology is used to repair and replace damaged tissues.
What does Tissue Regenix Group plc do?
Tissue Regenix Group plc is a medical technology company focused on developing and commercializing regenerative medicine products. Its core technology, dCELL, is a decellularization process that removes DNA and cellular material from tissues, creating biocompatible scaffolds for tissue repair and regeneration.
What are the main risks for TSSNF?
The main risks for Tissue Regenix Group plc include competition from larger medical device companies, regulatory hurdles and delays in product approvals, and potential patent expiration and intellectual property challenges. The company's negative profitability and reliance on future funding also pose significant risks.
What are the key factors to evaluate for TSSNF?
Tissue Regenix Group plc (TSSNF) holds an AI score of 43/100 (low). Tissue Regenix Group plc presents a compelling, albeit speculative, investment thesis centered on its proprietary dCELL technology and its applications in the growing regenerative medicine market. Not financial advice.
How frequently does TSSNF data refresh on this page?
TSSNF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TSSNF's recent stock price performance?
Tissue Regenix Group plc (TSSNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary dCELL technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TSSNF overvalued or undervalued right now?
Tissue Regenix Group plc (TSSNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TSSNF before investing?
Before investing in Tissue Regenix Group plc (TSSNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TSSNF to a portfolio?
Key strength of Tissue Regenix Group plc (TSSNF): Proprietary dCELL technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated or incomplete due to limited disclosure requirements for OTC stocks.
- Analyst coverage may be limited due to the company's size and market capitalization.